Literature DB >> 9428783

Risk factors for cervical cancer in Thailand: a case-control study.

S Chichareon1, R Herrero, N Muñoz, F X Bosch, M V Jacobs, J Deacon, M Santamaria, V Chongsuvivatwong, C J Meijer, J M Walboomers.   

Abstract

BACKGROUND: Human papillomaviruses (HPV) types 16 and 18 are clearly involved in the etiology of cervical cancer, but the evidence for the carcinogenicity of other HPV types is limited. Cofactors involved in the progression from infection with HPV to high-grade precursors and cancer have not been clearly defined by the results of previous studies.
METHODS: We conducted a hospital-based, case-control study of invasive cervical cancer to investigate risk in relation to HPV infection and its epidemiologic cofactors in Hat-Yai, Thailand. A total of 338 patients with squamous cell carcinoma, 39 patients with adenocarcinoma/adenosquamous carcinoma, and 261 control subjects were included in the study and were interviewed to obtain information with regard to cervical cancer risk factors. HPV DNA presence in cervical exfoliated cells or frozen biopsy specimens was determined by a polymerase chain reaction assay.
RESULTS: HPV DNA was detected in 95% of patients with squamous cell carcinoma, 90% of those with adenocarcinoma/adenosquamous carcinoma, and 16% of control subjects. For patients with squamous cell carcinoma, the most common types of HPV found were type 16 (60% of the positives), type 18 (18%), type 58 (3%), type 52 (3%), and type 31 (2%). For patients with adenocarcinoma/adenosquamous carcinoma, the most common HPV types found were type 18 (60% of the positives), type 16 (37%), and type 45 (3%). The risk factors that remained associated with risk of both histologic types after adjustment for HPV and their mutual confounding effects were limited education, increasing number of sexual partners, history of venereal diseases, and interval since last Pap smear (i.e., cytologic) test. Among patients with squamous cell carcinoma, some association with smoking was also observed.
CONCLUSION: New preventive strategies for cervical cancer will require the consideration of multiple HPV types.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9428783     DOI: 10.1093/jnci/90.1.50

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  34 in total

1.  Screening for cervical cancer: should we test for infection with high-risk HPV?

Authors:  C J Meijer; P J Snijders; A J van den Brule
Journal:  CMAJ       Date:  2000-09-05       Impact factor: 8.262

2.  Undetected human papillomavirus DNA and uterine cervical carcinoma: Association with cancer recurrence.

Authors:  Kae Okuma; Hideomi Yamashita; Terufumi Yokoyama; Keiichi Nakagawa; Kei Kawana
Journal:  Strahlenther Onkol       Date:  2016-01       Impact factor: 3.621

Review 3.  The causal relation between human papillomavirus and cervical cancer.

Authors:  F X Bosch; A Lorincz; N Muñoz; C J L M Meijer; K V Shah
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

4.  comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders.

Authors:  Maaike A P C van Ham; Judith M J E Bakkers; Gonneke K Harbers; Wim G V Quint; Leon F A G Massuger; Willem J G Melchers
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

5.  Socio-Demographic, Reproductive and Clinical Profile of Women Diagnosed with Advanced Cervical Cancer in a Tertiary Care Institute of Delhi.

Authors:  Neha Dahiya; Damodar Bachani; Anita S Acharya; D N Sharma; Subhash Gupta; K P Haresh
Journal:  J Obstet Gynaecol India       Date:  2016-06-13

6.  Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evaluation and follow-up.

Authors:  W J Melchers; J M Bakkers; J Wang; P C de Wilde; H Boonstra; W G Quint; A G Hanselaar
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

7.  Prevalence and determinants of Chlamydia trachomatis infections in women from Bogota, Colombia.

Authors:  M Molano; E Weiderpass; H Posso; S A Morré; M Ronderos; S Franceschi; A Arslan; C J L M Meijer; N Muñoz; A J C van den Brule
Journal:  Sex Transm Infect       Date:  2003-12       Impact factor: 3.519

8.  Prevalence of HPV infection among Greek women attending a gynecological outpatient clinic.

Authors:  Petroula Stamataki; Athanasia Papazafiropoulou; Ioannis Elefsiniotis; Margarita Giannakopoulou; Hero Brokalaki; Eleni Apostolopoulou; Pavlos Sarafis; George Saroglou
Journal:  BMC Infect Dis       Date:  2010-02-15       Impact factor: 3.090

9.  Differences in the risk of cervical cancer and human papillomavirus infection by education level.

Authors:  S Franceschi; M Plummer; G Clifford; S de Sanjose; X Bosch; R Herrero; N Muñoz; S Vaccarella
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

10.  Human papillomavirus infection in Honduran women with normal cytology.

Authors:  N Tábora; J M J E Bakkers; W G V Quint; L F A G Massuger; J A Matute; W J G Melchers; A Ferrera
Journal:  Cancer Causes Control       Date:  2009-08-15       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.